BBB seminar: Daniel Rauh
Department of Chemistry and Chemical Biology, TU Dortmund University, Germany
Research in our lab is dedicated to medicinal chemistry, compound screening technologies and chemical biology approaches. It is our goal to develop, synthesize and facilitate desperately needed tools to study target protein function in cells and organisms to push research to exciting new frontiers. In our research, we employ organic synthesis, biochemical and cellular compound screening, structural biology, structure-based design as well as target identification for the development of inhibitors and functional probes to perturb proteins of interest. We work in a highly interdisciplinary environment and very much appreciate collaborations with colleagues from other disciplines and the pharmaceutical industry. A strong focus in the lab is on personalized medicine for the treatment of cancer. Here, we closely collaborate with clinical oncologists to better understand the mechanisms of drug resistance and to develop compounds to overcome acquired drug resistance in non-small-cell lung cancer and gastrointestinal stromal tumors. We are motivated by the expectation that our techniques and investigations will lead to a better understanding of the molecular and cellular causes of fatal diseases and stimulate the development of new drugs. Some of the labs’ research initiatives will be outlined.
 J. Engel, et al., Angew Chem Int Ed Engl 2016, in press.
 a) S. C. Mayer-Wrangowski, et al., Angew Chem Int Ed Engl 2015, 54, 4379-4382; b) R. Schneider, et al., J Am Chem Soc 2013, 135, 6838-6841; c) J. R. Simard, et al., Nat Chem Biol 2009, 5, 394-396.
 J. Weisner, et al., Angew Chem Int Ed Engl 2015, 54, 10313-10316.
 J. M. Heuckmann, et al., J Clin Oncol 2012, 30, 3417-3420.
 F. Dietlein, et al., Cell 2015, 162, 146-159.
 M. L. Sos, et al., Cancer Res 2010, 70, 868-874.
 A. Richters, et al., J Med Chem 2013, 56, 5757-5772.
Chairperson: Ruth Brenk, Department of Biomedicine